跳至主要内容
临床试验/NCT07226934
NCT07226934招募中不适用

Feasibility and Preliminary Efficacy of GPT-QPL: An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

Washington University School of Medicine1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2025年12月26日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
40
试验地点
1
主要终点
Changes in communicative self-efficacy

研究概览

简要总结

The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized question prompt list (a list of suggested questions to ask during outpatient appointments) for patients with hematologic cancers. The intervention will involve tailoring a standardized prompt to patients' individual characteristics and concerns. This prompt will then be used to ask Washington University's (WashU) HIPAA compliant ChatGPT to generate personalized question lists for outpatient appointments. Analyses will assess the impact of personalized QPLs on patients' question-asking behavior; communicative self-efficacy; and self-reported amount and satisfaction with information obtained about their disease and its treatment. Sub-analyses will explore patterns in questions generated by WashU ChatGPT. Patients will also provide feedback pertaining to the perceived helpfulness and ease-of-use of WashU-ChatGPT-generated question lists, as well as their attitudes and intentions regarding use of AI chatbots and whether they would engage in pre-appointment AI-assisted question brainstorming independently in the future.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Dr. David Russler-Germain: Outpatient Lymphoma Clinic
  • Dr. Michael Slade: Outpatient Multiple Myeloma Clinic
  • Dr. Dilan Patel: Outpatient Lymphoma Clinic
  • Undergoing infusion or injection-based systemic therapy intended to cure or manage the disease, as opposed to regimens delivered solely for palliative purposes, at a frequency of once every 1-4 weeks.
  • For eligible patients with lymphoma, this includes, but is not limited to, commonly prescribed treatment combinations such as R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin/Hydroxydaunorubicin, Vincristine, and Prednisone) for Non-Hodgkin Lymphoma, or ABVD (Adriamycin/Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine) for Hodgkin Lymphoma-both regimens that are frequently administered every three weeks
  • For patients with multiple myeloma, eligibility will include patients in the "induction" phase of chemotherapy treatment, which frequently requires patients to come in for outpatient appointments once every four weeks as well as patients in a maintenance phase of treatment that otherwise requires them to attend outpatient appointments at a frequency of every one to four weeks
  • Between the ages of 18-99 at enrollment (Patients older than 99 will be excluded so that the study team is able to elicit questions from WashU ChatGPT using a standardized prompt that describes the patient's age only as specifically as a 10-year decade range (i.e., "I am a patient in my 20's, 30's, 40's, etc. Patients who are 18 or 19 years old will be described in the following manner: "I am a young adult patient in my late teens").
  • Able to consent to medical care independently (does not have a legally authorized representative or documented diagnosis of cognitive impairment)
  • Eligibility Criteria as determined by subsequent recruitment phone call or In-person approach after a clinic appointment:
  • Does not have visual impairments or English literacy limitations that would interfere with ability to engage in an intervention that requires being able to read material on an electronic device and on paper and communicate aloud during appointments with health care providers, based on patient self-report
  • Able to use email (consent form will be distributed electronically through DocuSign and associated emails), based on successful completion of electronic informed consent

排除标准

  • 未提供

研究组 & 干预措施

GPT-QPL: An AI-Generated, Personalized Question Prompt List

Experimental

Participants will complete surveys at appointment 1 (pre-intervention) and after being provided the AI-Generated, Personalized Question Prompt List at appointment 2 (post-intervention).

干预措施: GPT-QPL (Other)

结局指标

主要结局

Changes in communicative self-efficacy

时间窗: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)

* Communicative self-efficacy is measured by Self-efficacy survey . * Dependent samples t-tests will be used to assess within-subject changes. * The Self-Efficacy survey consists of two scales containing 10 questions each, with answers ranging from 1=not successful to 5=very successful or 1=not confident to 5=very confident. The total score on each scale ranges from 10-50 with a higher score on Scale 1 (the PEPPI-5) representing higher self-efficacy related to communicating with physicians in general and a higher score on Scale 2 (researcher-designed questions based on Social Cognitive Theory) representing higher self-perceived success at communication with the physician during the immediately preceding appointment.

次要结局

  • Changes in perceived amount of cancer information received as measured by an abbreviated version the EORTC QLQ - INFO25(Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks))
  • Changes in satisfaction with cancer information received as measured by the EORTC QLQ - INFO25(Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks))
  • Changes in the number of questions asked during appointments(Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks))
  • Changes in self-reported degree of intention to use AI chatbots for healthcare tasks(Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验